Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

The failure of Pfizer Inc.’s obesity pill, its highest profile experimental drug, raises the odds that the drugmaker will ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

A company official said in a statement that Pfizer still plans to develop other potential obesity treatments in earlier stages of testing. Obesity treatments have become one of the more promising ...

Danuglipron: According to the company's latest statement, one patient experienced a potential liver injury that may have been ...

Josh Shapiro’s residence being treated at hospital, police say A company official said in a statement that Pfizer still plans to develop other potential obesity treatments in earlier stages of ...

Advertisement Advertisement A company official said in a statement that Pfizer still plans to develop other potential obesity treatments in earlier stages of testing. Read More: Weight-Loss Drugs ...

Before going over this late-stage trial, plus any catalysts to be released from this program, it is first important to go over what this disorder is. Acquired Hypothalamic obesity is a rare ...

Pfizer will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to ...

Progression of obesity-associated metabolic abnormalities can be reversed by immunotherapy, according to a new study published in Nature Medicine. Researchers from the University of Toronto and ...

Company will instead invest in earlier-stage treatments for obesity Pfizer Inc. will stop developing an obesity pill that has been closely watched by investors. AFP Pfizer Inc. will stop ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Danish biopharma powerhouse Novo Nordisk is taking ...